Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > David M. Stout Joins NanoBio Corporation's Board of Directors

Abstract:
NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the appointment of David M. Stout to its Board of Directors. Mr. Stout most recently served as President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals.

David M. Stout Joins NanoBio Corporation's Board of Directors

ANN ARBOR, MI | Posted on May 29th, 2008

"We are pleased to welcome David to our Board of Directors and look forward to benefiting from his guidance and contributions," said James R. Baker Jr., M.D., chairman of NanoBio Corporation. "David's 30-plus years of experience in all facets of the pharmaceutical industry -- including his recent experience as head of global pharmaceutical operations for GSK, a world leader in infectious diseases -- will be invaluable to NanoBio as we approach the commercialization of our lead anti-infective and vaccine product candidates."

NanoBio's lead products are topical lotions and mucosal vaccines to combat a wide array of viruses, bacteria and fungi. They include topical treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and bacterial skin infections (including MRSA), as well as mucosal vaccines for seasonal and pandemic influenza, hepatitis B and RSV. The company's nanoemulsion-based products have demonstrated potent antimicrobial effects in several clinical trials, without safety concerns or systemic absorption. The products use a physical mode of action rather than chemical synthesis to disrupt pathogen membranes, rendering the emergence of drug resistance unlikely.

"The platform technology upon which NanoBio's products are based represents a truly novel approach to combating infections and provides a rich pipeline of anti-infective products and vaccines for the future," Stout said. "Given the company's recent and very compelling clinical results, I am particularly excited to be joining the company's board at this time. I look forward to working with NanoBio's management in bringing these new therapies and vaccines to the market."

In his most recent position as President of Pharmaceutical Operations at GSK, Mr. Stout led all global commercial activities, global manufacturing and all vaccine-related activities, including research and development, as well as other executive functions. Additionally, Mr. Stout directed the corporate pandemic flu preparedness program, an international effort that supports governments, health authorities and company employees around the world in planning to respond to a global influenza pandemic. Prior to his tenure at GSK, Mr. Stout held executive leadership positions at Glaxo Wellcome, SmithKline Beecham and Schering-Plough Corporation.

####

About NanoBio(R) Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
John Coffey
Vice President
Business Development
NanoBioCorporation
+1-734-302-9107

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Announcements

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Aculon Hires New Business Development Director December 19th, 2014

Nanomedicine expert joins Rice faculty: Gang Bao combines genetic, nano and imaging techniques to fight disease December 17th, 2014

Nexeon Attracts ex-Nokia Product Executive to its Board of Directors December 15th, 2014

Arrowhead Appoints Patrick O'Brien as General Counsel December 4th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE